Welcure Drugs & Pharmaceuticals
add_icon

Welcure Drugs & Pharmaceuticals

0.53
-0.01
(-1.85%)
Market Cap
₹67.92 Cr
PE Ratio
2.00
Volume
96,60,183.00
Day High - Low
₹0.54 - ₹0.53
52W High-Low
₹1.44 - ₹0.48
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
67.92 Cr
EPS
0.36
PB Ratio
0.52
Book Value
1.09
EBITDA
2.80
Dividend Yield
0.00 %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
1.19
Forecast For
Actual
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,831.60
#1 4,39,462.19
40.68
#1 54,729.00
9.71
#1 10,980
2.89
79.43
6,477.00
1,71,944.00
69.05
9,712.00
18.67
2,191
35.10
49.62
3,720.60
1,25,922.01
58.80
11,539.40
6.99
1,911
30.46
53.11
1,531.30
1,23,691.38
22.73
28,409.50
7.12
5,291
3.71
50.63
1,258.80
1,05,061.18
#1 18.15
33,741.20
16.73
5,725
-0.38
57.24
2,082.20
95,105.43
21.34
22,909.50
13.74
3,306
#1 72.75
65.07
942.50
94,837.55
18.56
23,511.00
18.55
4,615
34.60
44.36
2,251.00
92,911.94
52.05
12,744.20
#1 20.90
2,007
-21.05
38.76
1,226.70
71,246.94
20.70
32,345.60
9.43
3,484
3.81
63.81
5,685.00
67,972.70
28.29
13,458.30
3.70
2,216
10.98
53.82
Growth Rate
Revenue Growth
26,400.00 %
Net Income Growth
-1,200.00 %
Cash Flow Change
-1,70,692.31 %
ROE
-116.26 %
ROCE
-109.43 %
EBITDA Margin (Avg.)
-107.13 %

Yearly Financial Results

Annual Financials
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
Revenue
0
0
0
0
0
0
0
0
0
0
27
390
Expenses
0
0
0
0
0
0
0
0
0
0
24
345
EBITDA
0
0
0
0
0
0
0
0
0
-0
3
45
Operating Profit %
7 %
32 %
31 %
-41 %
3 %
-12 %
41 %
22 %
0 %
0 %
4 %
10 %
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
0
0
0
0
0
0
0
0
0
-0
3
45
Tax
0
0
0
0
0
0
0
0
0
0
1
11
Net Profit
0
0
0
0
0
0
0
0
0
-0
2
34
EPS in ₹
0.00
0.07
0.02
-0.02
0.00
-0.01
0.05
0.02
0.08
-0.13
0.36
3.20

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
0
0
0
0
0
0
0
0
2
1
267
Fixed Assets
0
0
0
0
0
0
0
0
0
0
0
Current Assets
0
0
0
0
0
0
0
0
0
0
182
Capital Work in Progress
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
0
0
0
0
0
0
Other Assets
0
0
0
0
0
0
0
0
1
1
267
Total Liabilities
0
0
0
0
0
0
0
0
2
1
267
Current Liabilities
0
0
0
0
0
0
0
0
0
0
41
Non Current Liabilities
0
0
0
0
0
0
0
0
0
0
123
Total Equity
-0
0
0
0
0
0
0
0
2
1
103
Reserve & Surplus
-12
-12
-12
-12
-12
-12
-12
-12
-12
-12
-10
Share Capital
12
12
12
12
12
12
12
12
13
13
112

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
0
0
0
0
0
0
0
0
-0
0
0
Investing Activities
0
0
0
0
0
0
0
0
0
0
-0
Operating Activities
0
-0
0
0
0
0
0
0
0
-0
-222
Financing Activities
0
0
0
0
0
0
0
0
-0
0
222

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Promoter
14.12 %
14.12 %
14.12 %
14.12 %
14.12 %
14.12 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
DIIs
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.01 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
73.82 %
73.81 %
75.07 %
76.27 %
76.04 %
76.91 %
88.34 %
93.73 %
93.64 %
93.68 %
94.28 %
93.87 %
93.69 %
93.14 %
93.55 %
98.79 %
98.99 %
98.74 %
91.83 %
Others
12.04 %
12.05 %
10.80 %
9.59 %
9.82 %
8.95 %
11.65 %
6.26 %
6.34 %
6.32 %
5.72 %
6.13 %
6.31 %
6.86 %
6.45 %
1.21 %
1.01 %
1.26 %
8.17 %
No of Share Holders
16,542
16,524
17,380
18,909
18,951
20,463
24,699
29,075
29,013
29,251
29,593
29,957
31,530
31,045
30,218
30,605
32,366
37,298
76,954

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
30 Sept 2024 0.67 0.70
14 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Nov 2024 0.70 0.73
14 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
14 Feb 2025 0.94 0.84
29 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
29 May 2025 1.01 1.08
05 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Aug 2025 0.86 0.88
27 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
27 Sept 2025 0.80 0.55
22 Aug 2025 SPLIT Split
1:10
16 Oct 2025 1.14 1.14
16 Oct 2025 BONUS Bonus
1:10
16 Oct 2025 0.60 0.74
13 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
13 Nov 2025 0.55 0.61

Announcements

Board Meeting Intimation for Postponement Of Board Meeting Which Was To Be Held On Thursday 27Th November 20253 days ago
Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday November 27 20255 days ago
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2025
Result- Unaudited Financial Statement For The Quarter And Half Year Ended 30Th September 2025Nov 13, 2025
Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Welcure Drugs & Pharmaceuticals Limited Held On Today I.E. Thursday 13Th November 2025.Nov 13, 2025
Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results For The Quarter And Half Year Ended September 30 2025 Along With Limited Review Report (Financial Results).Nov 08, 2025
Board Meeting Outcome for Outcome Of The Board Meeting-Allotment Of Bonus SharesOct 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Intimation Of Record Date For Ascertaining The Eligibility Of The Shareholders Entitled To Stock Split/ Sub-Division Of Shares & Bonus Issue.Oct 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 07 October2025 Of Welcure Pharmaceuticals LimitedOct 07, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 30, 2025
Board Meeting Outcome for Outcome Of The Board MeetingSep 27, 2025
Announcement under Regulation 30 (LODR)-Meeting UpdatesSep 27, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 27, 2025
Closure of Trading WindowSep 27, 2025
Board Meeting Intimation for Notice Regarding Postponement And Rescheduling Of The Board MeetingSep 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 04, 2025
Board Meeting Intimation for To Take On Record And Deliberate Upon The Letter Of Intent (LOI) Received From Telexcell Trade PTE LTD SingaporeSep 04, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Notice Of 33Rd Annual General Meeting Of Welcure Drugs & Pharmaceuticals LimitedSep 02, 2025
Reg. 34 (1) Annual Report.Sep 02, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 02, 2025
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sSep 02, 2025
Announcement/Information Under Regulation 44 Of SEBI (LODR) Regulations 2015 Regarding Providing Remote E-Voting Facilities For The Of Annual General Meeting To Be Held On 27" Septembers 2025.Sep 02, 2025
Corporate Announcement/Information Under Regulation 42 Of SEBI (LODR) Regulations 2015 Regarding Book Closure And Intimation Of Date Of The 33Rd Annual General Meeting.Sep 02, 2025
Board Meeting Outcome for Outcome Of Meeting Of The Board Of Directors Under The Regulation 29 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Sep 02, 2025
Board Meeting Intimation for Approval Of Business Related To AGM And Other MattersAug 28, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On August 28 2025Aug 28, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On 22.08.2025Aug 22, 2025
Announcement under Regulation 30 (LODR)-Resignation of Statutory AuditorsAug 21, 2025
Board Meeting Intimation for Intimation Under Regulation 30 Of SEBI (LODR) - Proposed Agro-Pharma Research Laboratory & Board Meeting On 28 August 2025 To Consider Fund-Raising By QIPAug 20, 2025
Clarification / Correction Under Regulation 30 Of SEBI (LODR) 2015 - Intimation Of Board Meeting Dated 11 August 2025.Aug 12, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 11, 2025
Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (LODR) 2015 - Proposal For Stock Split And Bonus IssueAug 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorAug 05, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorAug 05, 2025
Intimation Regarding Reconstitution Of Committees Of The Board Of Directors.Aug 05, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorAug 05, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorAug 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 05, 2025
Standalone Unaudited Financial Results For The 1St Quarter Ended 30Th June 2025Aug 05, 2025
Board Meeting Outcome for Outcome Of Board MeetingAug 05, 2025
Board Meeting Intimation for Intimation Of Meeting Of The Board Of Directors Under The Regulation 29 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Jul 31, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 21, 2025
Completion Of Export-Sourcing Orders Aggregating Rs. 299.91 CroresJul 08, 2025
Welcure Wins New ? 856 Million Export-Sourcing Orders From Giant Exim & Ravina International - Reg-30 DisclosureJun 30, 2025

Technical Indicators

RSI(14)
Neutral
38.81
ATR(14)
Less Volatile
0.03
STOCH(9,6)
Oversold
19.44
STOCH RSI(14)
Oversold
11.19
MACD(12,26)
Bullish
0.00
ADX(14)
Weak Trend
12.68
UO(9)
Bearish
45.59
ROC(12)
Downtrend And Accelerating
-13.11
WillR(14)
Oversold
-100.00